CYPH Stock Forecast: Cypherpunk Technologies, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Cypherpunk Technologies, Inc. hold a median 12-month price target of $0.9 — +41.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 1 Aug 2026 — in the lower half.
CYPH stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Cypherpunk Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Volatility (20): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Cypherpunk Technologies, Inc. — and when they’d sell — is the membership.
CYPH stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CYPH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +41.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 July 2026 | Cantor Fitzgerald | Initiates | Overweight | $0.90 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CYPH analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Cypherpunk Technologies, Inc. (CYPH) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 15.5×
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- −1.6×
Cheaper than 46% of US stocks
Cheaper than 81% of US stocks
Cheaper than 70% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −108.2%
- Return on assets
- −26.2%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CYPH vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYPH appears on the weeks it earns a place.
Frequently asked questions about CYPH stock
What is the CYPH stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Cypherpunk Technologies, Inc. have a median 12-month price target of $0.9, with estimates ranging from $0.9 to $0.9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CYPH stock a buy right now?
Of the 1 analysts covering Cypherpunk Technologies, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cypherpunk Technologies, Inc. 49 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CYPH?
As at 1 Aug 2026, Cypherpunk Technologies, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
Will CYPH stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +41.3% from the last close, and Ticker Nerd's factor model ranks Cypherpunk Technologies, Inc. 49 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CYPH stock forecast for 2030?
No analyst covering Cypherpunk Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.9 to $0.9 over the next 12 months.
How has CYPH stock performed over the past year?
Cypherpunk Technologies, Inc. returned +108.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cypherpunk Technologies, Inc. do?
Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches.
About Cypherpunk Technologies, Inc.
Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches. The company’s lead clinical-stage candidate, DKN-01, is a monoclonal antibody designed to inhibit Dickkopf-related protein 1 and is currently being evaluated in multiple clinical trials for esophagogastric, gynecologic, and colorectal cancers. Additional pipeline assets include FL-301, targeting Claudin18.2-expressing cells, and preclinical programs FL-302 and FL-501. Cypherpunk Technologies also distinguishes itself with a unique digital asset treasury strategy, actively acquiring and holding Zcash (ZEC) as part of its long-term value-building initiative. The company’s research and development operations are conducted through its wholly-owned subsidiary, Leap Therapeutics, Inc. Headquartered in Cambridge, Massachusetts, Cypherpunk Technologies operates at the intersection of biotechnology innovation and digital asset investment, reflecting its dual commitment to advancing cancer therapies and supporting privacy-focused technologies.
CEO Mr. Douglas E. Onsi J.D. · 6 employees · United States · https://www.cypherpunk.com